WHO ICTRP trial
Pulsed oral sirolimus in autosomal dominant polycystic kidney disease
EUCTR2012-000550-60-AT · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2012-000550-60-AT |
|---|---|
| Public title | Pulsed oral sirolimus in autosomal dominant polycystic kidney disease |
| Scientific title | Pulsed oral sirolimus in autosomal dominant polycystic kidney disease - The Vienna RAP Study |
| Primary sponsor | Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3 |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no |
| Countries | Austria |
| Conditions | Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal tubular cells, which compress and/or… |
| Interventions | Trade Name: Rapamune 1mg tablets Product Name: Rapamune 1mg tablets Pharmaceutical Form: Coated tablet INN or Proposed INN: SIROLIMUS CAS Number: 53123-88-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number… |
| Registration date | Nov 27, 2013 |
| Target size | 68 |
| Secondary IDs | V7/22032018;NCT02055079;1060/2012;7251768 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: